Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor

Cancer Research

Volumn 60, Issue 22, 2000, Pages 6253-6258

  Gerber, H P ^a   Kowalski, J ^a   Sherman, D ^a   Eberhard, D A ^a   Ferrara, N ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; HUMAN; HUMAN CELL; HYPOXIA; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; RHABDOMYOSARCOMA; TUMOR BLOOD FLOW; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; CELL DIVISION; ENDOTHELIAL GROWTH FACTORS; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; INJECTIONS, INTRALESIONAL; LYMPHOKINES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RNA; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033708398     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Angiogenesis in cancer, vascular, rheumatoid and other disease
2. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
3. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
4. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
5. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
6. VEGF is required for growth and survival in neonatal mice
7. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody
8. Vascular endothelial growth factor is essential for corpus luteum angiogenesis
9. Randomized Phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
10. A Randomized Phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer
11. VEGF receptor signaling in tumor angiogenesis
12. VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface
13. Delivery of molecular medicine to solid tumors
14. Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen
15. Determination of subcutaneous tumor size in athymic (nude) mice
16. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans
17. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders
18. 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration
19. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes
20. The biology of vascular endothelial growth factor
21. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR
22. Vascular endothelial growth factor B, a novel growth factor for endothelial cells
23. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
24. Tumor induction of VEGF promoter activity in stromal cells
25. In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin